4-(呋喃-2-基)苯硼酸频那醇酯 | 868755-79-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(呋喃-2-基)苯硼酸频那醇酯
• 英文名称: 4-(fur-2-yl)benzeneboronic acid pinacol ester
• 英文别名: 2-(4-(furan-2-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane；2-(4-(2-furanyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane；pinacol(4-(furan-2-yl)phenyl)boronate；2-[4-(furan-2-yl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS: 868755-79-7
• 化学式: C₁₆H₁₉BO₃
• 分子量: 270.136
• InChiKey: PUCSCLCOEROOCP-UHFFFAOYSA-N

物化性质

• 熔点：
  61 °C
• 沸点：
  368.3±25.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.25
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  31.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932190090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(呋喃-2-基)苯硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 methyl (E)-6-(2-((4-(4-(furan-2-yl)phenyl)-1-methyl-1H-imidazol-5-yl)methyl)phenoxy)-4-methylhex-4-enoate
  参考文献：
  名称：

  Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)

  摘要：

  The X-ray structure of the previously reported PPAR delta modulator 1 bound to the ligand binding domain (LBD) revealed that the amide moiety in 1 exists in the thermodynamically disfavored cis-amide orientation. Isosteric replacement of the cis-amide with five-membered heterocycles led to the identification of imidazole 17 (MA-0204), a potent, selective PPAR delta modulator with good pharmacokinetic properties. MA-0204 was tested in vivo in mice and in vitro in patient derived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); 17 altered the expression of PPAR delta target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.

  DOI：

  10.1021/acsmedchemlett.8b00287
• 作为产物：
  描述：

  4-硝基苯酚三氟甲基磺酸酯 在 2-双环己基膦-2',6'-二甲氧基联苯 、 盐酸 、 potassium phosphate monohydrate 、 palladium on activated charcoal 、 氢气 、 palladium diacetate 、 三乙胺 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 甲苯 为溶剂， 生成 4-(呋喃-2-基)苯硼酸频那醇酯
  参考文献：
  名称：

  Design and synthesis of boronic acid inhibitors of endothelial lipase

  摘要：

  Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.043

文献信息

• [EN] SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS<br/>[FR] ANALOGUES PYRIDINE-PIPÉRAZINYL SUBSTITUÉS EN TANT QUE COMPOSÉS ANTIVIRAUX DU VRS
  申请人：JANSSEN R & D IRELAND

  公开号：WO2015014836A1

  公开（公告）日：2015-02-05

  The invention concerns novel substituted pyridine-piperazinyl analogues of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

  这项发明涉及一种具有抗病毒活性的新型取代吡啶-哌嗪类似物，特别是对呼吸道合胞病毒（RSV）复制具有抑制活性的化合物，其化学式为（I）。该发明还涉及制备这种新型化合物、包含这些化合物的组合物，以及用于治疗呼吸道合胞病毒感染的化合物。
• Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)
  作者：Bharat Lagu、Arthur F. Kluge、Effie Tozzo、Ross Fredenburg、Eric L. Bell、Matthew M. Goddeeris、Peter Dwyer、Andrew Basinski、Ramesh S. Senaiar、Mahaboobi Jaleel、Nirbhay Kumar Tiwari、Sunil K. Panigrahi、Narasimha Rao Krishnamurthy、Taisuke Takahashi、Michael A. Patane

  DOI：10.1021/acsmedchemlett.8b00287

  日期：2018.9.13

  The X-ray structure of the previously reported PPAR delta modulator 1 bound to the ligand binding domain (LBD) revealed that the amide moiety in 1 exists in the thermodynamically disfavored cis-amide orientation. Isosteric replacement of the cis-amide with five-membered heterocycles led to the identification of imidazole 17 (MA-0204), a potent, selective PPAR delta modulator with good pharmacokinetic properties. MA-0204 was tested in vivo in mice and in vitro in patient derived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); 17 altered the expression of PPAR delta target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.
• Design and synthesis of boronic acid inhibitors of endothelial lipase
  作者：Daniel P. O’Connell、Daniel F. LeBlanc、Debra Cromley、Jeffrey Billheimer、Daniel J. Rader、William W. Bachovchin

  DOI：10.1016/j.bmcl.2011.12.043

  日期：2012.2

  Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL. (C) 2011 Elsevier Ltd. All rights reserved.